...
首页> 外文期刊>Journal of neurology >Effect of botulinum toxin treatment on quality of life in patients with isolated lingual dystonia and oromandibular dystonia affecting the tongue
【24h】

Effect of botulinum toxin treatment on quality of life in patients with isolated lingual dystonia and oromandibular dystonia affecting the tongue

机译:肉毒杆菌毒素治疗对孤立性舌肌张力障碍和眶下肌张力障碍影响舌头患者生活质量的影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The purpose of this study was to investigate the impact of botulinum toxin (BoNT) treatment on the quality of life (QoL) for patients with prominent lingual dystonia (LD) using a disease-specific questionnaire, the oromandibular dystonia questionnaire-25 (OMDQ-25). This is a prospective, observational study of a cohort of 30 patients treated with BoNT injections for LD, with or without concurrent jaw dystonia. Primary efficacy outcome was the absolute difference between total OMDQ-25 baseline score and total OMDQ-25 scores 4 and 8 weeks after the treatment. Safety outcome was the occurrence of adverse effects. The mean total OMDQ-25 baseline score was 46.8 +/- 17.8. After BoNT treatment, there was a significant reduction in the mean total OMDQ-25 score at 4 weeks (38.2 +/- 17.6; p = 0.004), as well as at 8 weeks (39.6 +/- 18.1; p = 0.008). At the multiple regression analysis, a jaw deviation pattern (JDD) and high questionnaire baseline total score were detected as predictors of a better outcome, whilst associated jaw tremor was a predictor of poor outcome. In patients with JDD, jaw-opening muscles were more frequently injected and genioglossus less frequently than in patients without JDD. No major adverse events were detected. A consistent and measurable improvement in QoL, with good safety and tolerability, can be achieved in patients with prominent LD by injecting BoNT into genioglossus and/or other muscles of the oromandibular region.
机译:这项研究的目的是使用疾病特异性问卷-口腔颌下肌张力障碍问卷-25(OMDQ-)调查肉毒杆菌毒素(BoNT)治疗对重度舌肌张力障碍(LD)患者生活质量(QoL)的影响25)。这是一项针对30名接受BoNT注射液治疗LD的患者的前瞻性观察性研究,无论是否伴有下颌肌张力障碍。主要疗效结果是治疗后4周和8周总OMDQ-25基线评分与总OMDQ-25评分之间的绝对差异。安全后果是发生不良反应。平均OMDQ-25总基线评分为46.8 +/- 17.8。 BoNT治疗后,在第4周(38.2 +/- 17.6; p = 0.004)和第8周(39.6 +/- 18.1; p = 0.008),OMDQ-25的平均总得分显着降低。在多元回归分析中,检测到颌骨偏斜模式(JDD)和较高的问卷基线总分可作为预后较好的指标,而相关的颌骨震颤则可作为预后不良的指标。与没有JDD的患者相比,在JDD的患者中,张开肌肉的注射频率更高,舌肌的发生频率更低。没有发现重大不良事件。通过将BoNT注射到glo舌肌和/或口腔下颌骨其他肌肉中,可以在患有突出LD的患者中实现QoL的一致且可测量的改善,并具有良好的安全性和耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号